Drilldown: Medicines
Medicines > classes 
:
Analgesic or
Neuroleptic or
[[:Category:Antihistamines|First-generation antihistamine]]
:
Analgesic or
Neuroleptic or
[[:Category:Antihistamines|First-generation antihistamine]] Use the filters below to narrow your results.
generic:
Asenapine (1) ·
Butorphanol (1) ·
Chlorpromazine (1) ·
Codeine (2) ·
Cyproheptadine (hydrochloride) (1) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Droperidol (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Fluphenazine (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Hydroxyzine (hydrochloride; pamoate salt) (1) ·
Iloperidone (1) ·
Levorphanol (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Meperidine (1) ·
Molindone (1) ·
Nalbuphine (1) ·
Oxymorphone (1) ·
Paliperidone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Promethazine (hydrochloride) (1) ·
Tapentadol (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Trifluoperazine (1) ·
Ziprasidone (1)
brand:
None (5) ·
(multiple, generic dominant) (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Orap (1) ·
Periactin (US brand discontinued; generic widely available) (1) ·
Phenergan, Promethegan (suppositories) (1) ·
Prolixin (1) ·
Saphris (1) ·
Stadol (1) ·
Stelazine (1) ·
Talwin (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vicodin (1) ·
Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-00000017-QINU`"' Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients'"`UNIQ--ref-00000018-QINU`"'. (1) ·
'"`UNIQ--vote-0000001D-QINU`"' '''QT prolongation''' risk at high doses prompted the FDA's 2015 caution against use in patients with prolonged QT or with concurrent QT-prolonging medicines'"`UNIQ--ref-0000001E-QINU`"'. (1)
uses:
None (30) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)
starting dose:
None (30) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) ·
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID (1) ·
Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided (1)
preparations:
None (30) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) ·
Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) (1) ·
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) ·
Tablets 4 mg; oral syrup 2 mg/5 mL (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (30) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Limited human data; older agent with substantial use experience.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1)
legal:
None (31) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety'"`UNIQ--ref-00000028-QINU`"' (1)
Showing below up to 34 results in range #1 to #34.